பியோனா ஸ்டேபிள்டன் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from பியோனா ஸ்டேபிள்டன். Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In பியோனா ஸ்டேபிள்டன் Today - Breaking & Trending Today

US venture capital firm makes $221m investment in Octopus Deploy

US venture capital firm makes $221m investment in Octopus Deploy US venture capital firm makes $221m investment in Octopus Deploy Share Firm: Thomson Geer (Octopus Deploy). Deal: Octopus Deploy has secured an investment from Insight Partners. Value: $221 million. ); googletag.cmd.push(function() { googletag.display( div-gpt-ad-1606778613657-0 ); }); } Area: Finance. Key players: The Thomson Geer team comprised of partner David Schiavello, partner Peta Thompson, senior associate Chris Chin, senior associate Ray Marshall and law graduate Munir Abdul, supported by employment partner Andrew Cardell-Ree, tax partner George Hodson and tax senior associate Fiona Stapleton. Deal significance: Octopus Deploy is a Brisbane-based technology company established in 2011 by Brisbane couple Paul and Sonia Stovell. Octopus Deploy is used by over 25,000 organisations and automates complex software deployments. Since its inception the company has e ....

David Schiavello , Andrew Cardell , Gray Marshall , Fiona Stapleton , Sonia Stovell , Munir Abdul , George Hodson , Chris Chin , Thomson Geer , Emma Ryan , Peta Thompson , Octopus Deploy , Andrew Cardell Ree , Insight Partners , Thomson Geer Corporate , ராய் மார்ஷல் , பியோனா ஸ்டேபிள்டன் , ஜார்ஜ் ஹாட்சன் , கிறிஸ் கன்னம் , தாம்சன் கீர் , எம்மா ரியான் , பெட்டா தாம்சன் , நுண்ணறிவு கூட்டாளர்கள் ,

Revolutionary eye drop trial starts for common eye diseases

Date Time
Revolutionary eye drop trial starts for common eye diseases
Research conducted by UNSW Sydney has paved the way for clinical testing of an eye drop treatment for diabetic macular oedema and wet age-related macular degeneration, the leading causes of blindness in the developed world.
A clinical trial has commenced across Australia for a novel eye drop treatment that could improve the treatment of patients with retinal vascular diseases. If successful, the eye drops will revolutionise treatment for these diseases, which currently involves serial injections of an antibody into the back of the eye.
Based on initial work carried out at the UNSW School of Chemistry, Professor Jonathan Morris collaborated with Exonate Limited to design the molecule used in the trial. ....

New South Wales , Nicholas Fisk , Jonathan Morris , Fiona Stapleton , Vision Sciences , School Of Optometry , Janssen Pharmaceuticals Inc , School Of Chemistry , Janssen Pharmaceutical Companies Of Johnson , Professor Jonathan Morris , Exonate Limited , Professor Jonathan , Professor Fiona Stapleton , Vision Science , Deputy Vice Chancellor , Catherine Beech , Chief Executive Officer , Janssen Pharmaceuticals , Janssen Pharmaceutical Companies , University Of New South Wales , Unsw Sydney , Macular Degeneration , Vascular Disease , Clinical Trials , Health Care , புதியது தெற்கு வேல்ஸ் ,

Azura Ophthalmics Announces Primary Endpoints Met in Topline Results from Phase 2 Trial of the Company's Investigational Treatment for Contact Lens Discomfort

Azura Ophthalmics Announces Primary Endpoints Met in Topline Results from Phase 2 Trial of the Company’s Investigational Treatment for Contact Lens Discomfort
Significant improvement in multiple measures of Meibomian gland secretion and associated improvements in contact lens wear time
TEL AVIV, Israel & MELBOURNE, Australia (BUSINESS WIRE) Azura Ophthalmics Ltd., a clinical-stage company developing innovative therapies for Meibomian gland dysfunction (MGD) and related eye diseases, today announced topline results from a phase 2 clinical trial evaluating the company’s investigational therapy for the treatment of contact lens discomfort (CLD). The ECLIPTIC study examining Azura’s lead asset, AZR-MD-001, met its primary endpoints by showing statistically significant improvements in multiple measures of Meibomian gland secretion and patients’ ability to wear contact lenses as desired. Full data from the study will be submitted for presentation at an upcoming scientifi ....

Tel Aviv Yafo , Tel Aviv , Hannah Boxerman , Marc Gleason , Fiona Stapleton , Azura Ophthalmics Ltd , University Of New South Wales , School Of Optometry , International Workshop On Contact Lens Discomfort , New South , Contact Lens Dry Eye , Selenium Disulfide , Scientia Professor , Vision Science , Associate Dean , New South Wales , Dry Eye Disease , Dry Eye , Azura Ophthalmics , Opin Allergy Clin , Contact Lens Discomfort , தொலைபேசி அவிவ் யபோ , தொலைபேசி அவிவ் , மார்க் கிலேஅசோன் , பியோனா ஸ்டேபிள்டன் , அஸுரா கண் மருத்துவம் லிமிடெட் ,